logo-loader

Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement

Last updated: 16:46 17 Sep 2026 BST, First published: 15:15 17 Sep 2026 BST

dollars

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases. 

The companies also entered a private placement financing agreement expected to raise approximately $225 million in gross proceeds.

Shares of Lisata gained as much as 65% in early Thursday trading before settling around 20% higher just before the afternoon.

The acquisition was structured as a stock-for-stock transaction, with Marea's outstanding equity interests exchanged for 1.79 million shares of Lisata common stock and over 211 million shares of Series C non-voting convertible preferred stock, representing over 213 million shares of Lisata common stock on an as-converted basis.

Investors in the private placement will be issued an aggregate of 151 million shares of Series C non-voting convertible preferred stock, or 151 million shares of common stock on an as-converted basis, at a price of approximately $1,491.37 per share.

Following the transactions, equity holders of Lisata immediately prior to the acquisition will own approximately 2.39% of the company's common stock, Marea equity holders will own approximately 59.54%, and private placement investors will own approximately 38.07%, each on a fully-diluted, as-converted basis.

Lisata plans to use the proceeds primarily to advance MAR001/005 and MAR002 through key clinical milestones, including completion of an ongoing Phase 2b trial in patients with severe hypertriglyceridemia and a Phase 2 trial in patients with acromegaly. Both studies are expected to report topline data in the fourth quarter of 2027.

"After a thorough review of strategic alternatives, the acquisition of Marea marks a significant milestone for Lisata as we broaden our focus toward advancing Marea's product candidate portfolio, which addresses significant unmet need across a range of cardioendocrine diseases," said Dr David Mazzo, CEO of Lisata.

Dr Josh Lehrer, newly appointed Chief Operating Officer and President of Lisata and CEO of Marea, said the transaction provides resources to advance both clinical programs through pivotal milestones, including initiation of Phase 3 registrational studies.

The oversubscribed financing included participation from RA Capital Management, Forbion, Third Rock Ventures, Alpha Wave, Perceptive Advisors, Sofinnova Investments, Omega Funds, Surveyor Capital (a Citadel company), Columbia Threadneedle Investments, Nantahala Capital, Affinity Asset Advisors, LLC, venBio, Rock Springs Capital and other institutional investors.

S&U chairman targets stronger returns as receivables hit record £646m

S&U PLC (LSE:SUS) chairman Anthony Coombs talked with Proactive's Stephen Gunnion about record capital receivables of £646 million, up 16%, and plans to turn continued growth into stronger profitability across its Advantage motor finance and Aspen property bridging businesses.Coombs...

58 minutes ago